How to Market a Biotech or Medtech Crowdfunding Raise Without Violating FDA Promotion Rules

A biotech or medtech issuer can market an equity crowdfunding raise, but every investor-facing claim about an unapproved product sits under two rulebooks at once: FDA's prohibition on promoting investigational drugs and devices as safe or effective, and the federal securities antifraud rules that apply to anything said to sell the offering. In practice that means investor marketing can describe the science, the regulatory pathway, the trial stage and the risks factually, but it cannot claim the product works, imply FDA approval it does not have, or let campaign copy run ahead of the data. This guide maps the overlap, shows which claims typically survive review, and lays out a workflow issuers commonly use to keep a Reg CF, Reg D 506(c) or Reg A+ campaign clean.

Why Life-Sciences Raises Carry Two Layers of Risk

Most issuers only have to think about securities law when they write campaign copy. A pre-approval drug or device company also has to think about the Federal Food, Drug, and Cosmetic Act, because an investor ad is still a public statement about the product. FDA's rules do not carve out communications aimed at investors rather than patients or physicians.

For drugs, 21 CFR 312.7 states that a sponsor or investigator, or anyone acting on their behalf, shall not represent in a promotional context that an investigational new drug is safe or effective for the purposes under investigation. The same section notes that it is not intended to restrict the full exchange of scientific information, including dissemination of findings in scientific or lay media. For devices, 21 CFR 812.7 prohibits promoting or test marketing an investigational device until FDA has approved it for commercial distribution, and prohibits representing that it is safe or effective for the purposes being investigated.

The phrase "anyone acting on their behalf" matters for campaign teams. The issuer's marketing agency, the people writing ad copy, and any paid promoter are all working on behalf of the sponsor.

On the securities side, every Reg CF, Reg D and Reg A+ offering remains subject to antifraud liability. Rule 10b-5 makes it unlawful to make an untrue statement of a material fact, or to omit a material fact necessary to make statements not misleading, in connection with the purchase or sale of a security. An overstated efficacy claim in an investor ad is therefore a potential problem twice: FDA may view it as pre-approval promotion, and investors who bought on it may argue it was a material misstatement.

Claims That Typically Pass vs. Claims That Typically Fail

The workable dividing line is between describing facts about the program and asserting conclusions FDA has not reached. The table below reflects how life-sciences issuers and their counsel commonly sort campaign copy. It is a drafting aid, not a legal standard; final calls belong to regulatory and securities counsel.

The 510(k) row catches many medtech issuers. Under 21 CFR 807.97, a substantial-equivalence determination "does not in any way denote official approval of the device," and any representation that creates an impression of official approval because of a 510(k) is misleading and constitutes misbranding. "FDA-cleared" and "FDA-approved" are not interchangeable in campaign copy.

How Each Exemption Changes the Marketing Surface

FDA's rules apply identically across exemptions. What changes is how much an issuer can say outside the offering document, and therefore how many places an investigational-product claim can leak into.

For a deeper look at the Reg CF notice limits, see our breakdown of what a Rule 204 notice can and cannot say.

A Review Workflow Life-Sciences Issuers Commonly Use

The issuers that run clean campaigns treat claims review as a production step, not a final read-through. A typical sequence looks like this:

1. Build a claims library before any creative is written. Regulatory counsel and the clinical team agree on a fixed set of approved statements about the product, its stage, data and pathway. Copywriters draw from that library rather than paraphrasing the pitch deck.
2. Anchor every data point to a source. Each figure in campaign copy is traced to a publication, registry entry, conference abstract or the offering document. If a number cannot be sourced, it does not run.
3. Match the offering document. Campaign copy should not say anything the Form C, PPM or offering circular does not support. Disclosure under Rule 201 for Reg CF, and the corresponding disclosure for other exemptions, sets the ceiling for marketing claims.
4. Run dual review. Securities counsel reviews for antifraud and exemption compliance; FDA regulatory counsel reviews for pre-approval promotion and clearance-versus-approval language. One reviewer rarely covers both.
5. Lock creative variants. Paid social testing generates dozens of headline variants. Each variant goes through review, not just the first one approved.
6. Govern founder and team channels. Founder interviews, podcasts and LinkedIn posts are often the highest-risk surface because they are unscripted. Many issuers give spokespeople a short list of approved phrases and topics to avoid.
7. Separate patient recruitment from investor acquisition. Clinical trial recruitment ads typically go through IRB review and serve a different audience. Mixing recruitment messaging into investor funnels, or retargeting trial-site visitors with investment ads, blends two regulated activities that are better kept apart.
8. Update when the data changes. A trial readout, a clinical hold, an FDA meeting outcome or a delayed filing can make earlier copy stale. Issuers commonly pause ads, re-review active creative and assess with counsel whether an offering amendment is needed.

Where Life-Sciences Campaigns Usually Go Wrong

Paraphrasing the scientific deck

Science decks are written for informed audiences and often use shorthand like "demonstrated efficacy" for an early or exploratory signal. Lifted into a retail investor ad, that shorthand reads as a conclusion FDA has not reached.

Forward-looking timelines stated as fact

Approval and clearance dates depend on FDA review, trial enrollment and data. Copy that presents a regulatory milestone as certain creates exposure on both fronts. Our guide to forward-looking statements across Reg CF, Reg D and Reg A+ covers how issuers typically qualify projections.

Influencer and promoter content

Paid promoters are acting on behalf of the issuer. A health influencer who tells followers a product "changed my life" while promoting the raise can create pre-approval promotion and securities problems simultaneously. In Reg CF, Rule 205 requires anyone compensated to promote the offering through the platform's channels to disclose that compensation in each communication.

Comment sections and community management

Investors ask "does it work?" in comments and platform discussion boards. Answers from the issuer are communications on its behalf. Prepared, reviewed responses that point back to the trial stage and the offering document are the common defense.

Stale creative after a data event

An ad approved before a trial readout can become misleading after it. Campaigns that keep running evergreen creative through a material development are a recurring source of risk.

What Investor Marketing Can Still Do Well

The constraints narrow what can be claimed, not how well a campaign can be run. Life-sciences raises that perform tend to lean on elements that do not depend on efficacy claims:

• Team credibility: prior approvals, exits, publications and clinical experience of the founders and advisors, stated factually.
• Problem definition: the unmet medical need and current standard of care, sourced to published literature.
• Program transparency: trial design, endpoints, enrollment status and the regulatory pathway, explained in plain language.
• Milestone education: what a Phase 2 readout or a 510(k) submission means, and what can go wrong, so investors understand the risk profile.
• Risk-forward messaging: clear statements that the product is investigational, has not been approved or cleared by FDA, and may never be.

Founders exploring the category can also review our earlier piece on how health-tech companies approach equity crowdfunding.

Frequently Asked Questions

Can a biotech company say its drug works in an equity crowdfunding ad?

Not for an investigational drug. 21 CFR 312.7 prohibits a sponsor, or anyone acting on its behalf, from representing in a promotional context that an investigational new drug is safe or effective for the purposes under investigation. Issuers typically describe trial stage, endpoints and published results factually instead of stating conclusions about efficacy.

Is it misleading to call a 510(k)-cleared device FDA-approved?

Yes. Under 21 CFR 807.97, a 510(k) substantial-equivalence determination does not denote official approval, and any representation creating an impression of official approval is treated as misleading and as misbranding. Campaign copy for a cleared device typically uses "FDA-cleared" and limits claims to the cleared indication.

Do FDA promotion rules apply to investor marketing or only to patient advertising?

The FDA rules on investigational products apply to promotional representations by the sponsor or anyone acting on its behalf, and they do not carve out investor audiences. An investor ad, campaign video or founder interview that claims an unapproved product is safe or effective can raise the same concern as patient-facing promotion. Issuers typically ask FDA regulatory counsel to review investor materials.

Can a medtech issuer share clinical trial results during a Reg CF campaign?

Generally yes, if the results are reported accurately and in context. FDA's drug rule expressly preserves the exchange of scientific information, and securities rules require that disclosed information not be misleading. Issuers typically report endpoints, sample sizes and limitations as published, keep them consistent with the Form C, and avoid selective highlighting.

Which exemption is easiest for a pre-approval biotech to market under?

No exemption removes FDA's limits on investigational-product claims. Reg D 506(c) and Reg A+ permit broader advertising than Reg CF's Rule 204 notice, which means more creative to review rather than more freedom to make efficacy claims. The choice of exemption usually turns on raise size, investor base and disclosure cost, and is a question for securities counsel.

Building a Life-Sciences Raise That Survives Review

Biotech and medtech campaigns depend on credibility with investors who know a pre-approval company carries real risk. Growth Turbine has provided marketing support across more than $490M in aggregate issuer-reported totals and 210+ fundraising campaigns managed supported across Reg CF, Reg D 506(c), Reg A+ and tokenized securities offerings, spanning 23+ crowdfunding platforms and 25+ industries. Growth Turbine provides marketing services only; it is not a broker-dealer, law firm or FDA regulatory consultant, and it builds campaigns around the claims library and offering documents that the issuer's counsel has approved.

Planning a life-sciences raise? Our equity crowdfunding marketing services cover claims-controlled creative, compliant landing pages and investor funnels across Reg CF, Reg D and Reg A+. For retail-facing raises, see our Reg CF campaign services, then contact our team to scope the campaign.

Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute legal, financial, or investment advice. Always consult with qualified legal counsel and financial advisors before launching a capital raise.